Skip to main content

Table 5 Adjusted odds ratios for FN in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively (Narrow Definition of FN)

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

 

Adjusted Odds Ratio for FN (95% CI, p-value)*

Cycle 1

Cycle 2

Cycles ≥3

Last Cycle

All Cycles

Commercial

 Independent Variables

  No PEG Prophylaxis

4.2 (3.8–4.7, < 0.001)

4.1 (3.3–4.9, < 0.001)

3.3 (2.9–3.8, < 0.001)

3.2 (2.7–3.8, < 0.001)

4.2 (3.9–4.5, < 0.001)

  FN in Prior Cycle

–

5.1 (3.7–7.0, < 0.001)

5.9 (4.9–7.0, < 0.001)

3.9 (3.0–5.0, < 0.001)

3.1 (2.6–3.5, < 0.001)

  Regimen

   TAC

4.4 (3.8–5.1, < 0.001)

2.2 (1.6–3.2, < 0.001)

3.0 (2.4–3.8, < 0.001)

2.7 (2.0–3.6, < 0.001)

4.1 (3.3–5.2, < 0.001)

   TC

–

–

–

–

–

   TCH

1.0 (0.9–1.1, 0.963)

1.4 (1.1–1.8, 0.009)

1.2 (1.0–1.4, 0.130)

1.2 (0.9–1.5, 0.191)

1.3 (1.0–1.6, 0.040)

   CHOP±R

1.4 (1.2–1.6, < 0.001)

2.0 (1.5–2.7, < 0.001)

3.5 (2.9–4.4, < 0.001)

1.7 (1.4–2.1, < 0.001)

3.0 (2.0–4.5, < 0.001)

  Age

   18–49

–

–

–

–

–

   50–64

1.1 (1.0–1.2, 0.216)

1.1 (0.9–1.4, 0.332)

1.0 (0.9–1.2, 0.671)

1.3 (1.1–1.6, 0.010)

1.1 (1.0–1.2, 0.207)

   65–74

1.5 (1.3–1.8, < 0.001)

1.2 (0.8–1.6, 0.354)

1.4 (1.1–1.8, 0.002)

1.6 (1.2–2.1, 0.003)

1.4 (1.3–1.6, < 0.001)

   ≥ 75

2.1 (1.7–2.7, < 0.001)

1.7 (1.1–2.6, 0.012)

2.0 (1.5–2.6, < 0.001)

4.0 (2.9–5.5, < 0.001)

2.1 (1.7–2.4, < 0.001)

Medicare

 Independent Variables

  No PEG Prophylaxis

2.0 (1.9–2.2, < 0.001)

2.2 (2.0–2.5, < 0.001)

1.6 (1.5–1.8, < 0.001)

1.3 (1.2–1.4, < 0.001)

1.9 (1.8–2.0, < 0.001)

  FN in Prior Cycle

–

4.6 (4.0–5.3, < 0.001)

4.1 (3.8–4.4, < 0.001)

2.4 (2.1–2.6, < 0.001)

2.7 (2.5–2.9, < 0.001)

  Regimen

   TAC

3.1 (2.7–3.7, < 0.001)

2.5 (1.9–3.5, < 0.001)

2.8 (2.3–3.5, < 0.001)

2.5 (2.0–3.1, < 0.001)

2.7 (2.4–3.0, < 0.001)

   TC

–

–

–

–

–

   TCH

0.6 (0.6–0.7, < 0.001)

0.7 (0.5–0.9, 0.001)

0.6 (0.5–0.8, < 0.001)

0.7 (0.6–0.8, < 0.001)

0.6 (0.5–0.6, < 0.001)

  CHOP±R

1.6 (1.5–1.7, < 0.001)

2.1 (1.9–2.5, < 0.001)

2.9 (2.6–3.2, < 0.001)

2.1 (1.9–2.3, < 0.001)

1.9 (1.8–2.0, < 0.001)

  Age

  65–74

–

–

–

–

–

   75–84

1.2 (1.1–1.3, < 0.001)

1.0 (0.8–1.1, 0.759)

1.1 (1.0–1.2, 0.011)

1.2 (1.1–1.4, < 0.001)

1.1 (1.1–1.2, < 0.001)

   ≥ 85

1.4 (1.3–1.6, < 0.001)

1.1 (1.0–1.3, 0.047)

1.2 (1.1–1.4, < 0.001)

1.6 (1.5–1.8, < 0.001)

1.3 (1.3–1.4, < 0.001)

  1. FN febrile neutropenia, PEG pegfilgrastim, TC docetaxel + cyclophosphamide, TAC docetaxel + doxorubicin + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone, R rituximab
  2. *Adjusted for other characteristics of patients listed in Table 1; additional covariates selected via backward selection method